A novel combination therapy, CagriSema, which pairs the amylin analog drug cagrilintide with semaglutide, has entered phase 3 development in both type 2 diabetes and obesity
They have shown that treatment with ALC increases serum levels of other reproductive hormones, like estradiol, progesterone, LH and decreases prolactin in the usual fashion with different phases of estrous in animal [16, 17]
Some clinical trials in multiple sclerosis were conducted
While there is no official research specifically about semaglutide and insomnia, a social media study found user complaints about disrupted sleep as a result of the medication
It stressed that the drugs on their own were not enough to reverse obesity and that people using them should also eat more healthily, exercise more and have counselling about their lifestyles
Montelius, C., Erlandsson, D., Vitija, E., Stenblom, E.-L., Egecioglu, E., & Erlanson-Albertsson, C